PROJECT REPORT

ON

MERCK & CO

INTRODUCTION

One of the largest pharmaceutical company in the world both by market capitalization & revenue

Established in 1891 as the United States subsidiary of the German company now known as Merck KGaA

1917 as an independent company

Manufactures & markets broad range of products to improve human & animal health

LOGO

BASIC INFORMATION

Industry

Founded

Headquaters

Chairman

 President & CEO

Pharmaceuticals

1891 as a subsidiary of Merck KGaA

Whitehouse Station, New Jersey, United States

Richard T. clarck

Stanley F. Barshay

CONTINUED

Revenue

Operating Income

Net Income

Total assets

Total equity

Employees

 US$27.4 Billion

 US$4.83 Billion

 US$12.9 Billion

 US$112 Billion

US$59.1 Billion

61,500

VISION OF MERCK & CO.

We make a difference in the lives

of people globally through our innovative medicines, vaccines, and consumer health and animal products. We aspire to be the best healthcare company in the world and are dedicated to providing leading innovations and solutions for tomorrow.

MISSION OF MERCK & CO

To provide innovative,

distinctive products and services that save and improve lives and satisfy customer needs, to be recognized as a great place to work, and to provide investors with a superior rate of return.

WHAT WE STAND FOR ????

Excellence in science and healthcare innovation, with an emphasis on addressing unmet medical needs.

Focus on patients and

anticipating customers needs

CONTINUED

Commitment to expand access to our medicines and vaccines, and to improve global health

PRODUCTS WE DEAL IN ….

VACCINES

PRESCRIPTION PRODUCTS

CONSUMER PRODUCTS

ANIMAL HEALTH

PRESCRIBING INFORMATION

RESPONSIBILITY OF MERCK & CO.

ETHICS & TRANSPARENCY

ACCESS

ENVIRONMENT

COMMUNITY

OBJECTIVE OF MERCK & CO

To develop policy positions that guide our activities and advocacy on a range of issues

To seek opportunities to adopt industry-leading standards in several areas

To strive to communicate clearly and transparently about our positions

CONTINUED

To work closely with the many groups and individuals who are also trying to address the complex healthcare challenges that confront us

PRODUCTS ON THE MARKET

Antivenin - for the treatment of Black Widow Spider bites

Arcoxia (etoricoxib) - for the symptomatic treatment of osteoarthritis

Cancidas (caspofungin) - An echinocandins antifungal drug for treatment of Aspergillus and Candida

CONTINUED

Cosopt (dorzolamide and timolol) - reduces intraocular pressure in people with glaucoma or ocular hypertension.

Cozaar/Hyzaar (losartan)- used to treat hypertension, to reduce the risk of strokes and to treat diabetic nephropathy.

CONTINUED

Cozaar/Hyzaar (losartan)- used to treat hypertension, to reduce the risk of strokes and to treat diabetic nephropathy.

Crixivan (indinavir) – a protease inhibitor HIV medication.

Emend (aprepitant) – treats vomiting and nausea brought about by chemotherapy.

CONTINUED

Emend (aprepitant) – treats vomiting and nausea brought about by chemotherapy

Emend Injection (fosaprepitant dimeglumine) - an intravenous drug for nausea and vomiting caused by chemotherapy

Emflex (Acemetacin) - a non-steroidal anti-inflammatory drug

CONTINUED

Fosamax (alendronate) – osteoporosis medication.

Fosamax Plus D (alendronate/vitamin D) – osteoporosis medication

Isentress (raltegravir) - HIV integrase inhibitor.

COMMON ST. OF MERCK & CO

REVENUE GRAPH OF MERCK & CO.

COMPETITORS IN UK

NAMEOF THE COMPANY

TOTAL REVENUE (IN USD

BILLIONS)

45.83

32.81

1. GlaxoSmithKline

2. AstraZeneca

COMPETITORS IN USA

NAME OF THE COMPANY

1. Johnson & Johnson

2. Abbott Laboratories

3. Pfizer

4. Eli lilly

5. Bristol-Myers Squibb

TOTAL REVENUE(IN USD BILLIONS )

61.90

30.76

50.0

21.84

18.81

COMPETITORS IN SWITZERLAND

NAME OF THE COUNTRY

1. HOFFMAN LA ROCHE

2. NOVARTIS

3. NYCOMED

TOTAL REVENUE (IN USD BILLIONS) 47.35

44.27

4.26

COMPETITORS IN GERMANY

NAME OF THE COUNTRY

1. BAYER

2. BOEHRINGER INGELHEIM

3. MERCK kGaA

TOTAL REVENUE (IN USD BILLIONS)

22.3

16.9

5.17

COMPETITORS IN JAPAN

NAME OF THE COUNTRY

1. TAKEDAPHARMACEUTICAL

2. ASTELLAS PHARMA

3. DAIICHI SANKYO 9

4. EISAI

5. CHUGAI PHARMACEUTICAL .

TOTAL REVENUE (IN USD BILLIONS)

15.6

10.7

9

5.5

2.0

SELECTIVE PRODUCT :LISINOPRIL

It is a drug of the angiotensin converting enzyme (ACE) inhibitor class that is primarily used in treatment of hypertension, congestive heart failure, heart attacks and also in preventing renal and retinal complications of diabetes. It has been compared withomapatrilat which is of similar function.

SYSTEMATIC IMAGE

IDENTIFIERS

CAS number

ATC code

PubChemode

8C09AA03

3915-83-7

CID 5362119

CHEMICAL DATA

Formula

Mol. Mass

SMILES

InChI Synonyms

C21H31N3O5 

405.488 g/mol

Emolecules & Pubchem

(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid

Pharmacology

Lisinopril is the lysine-analog of enalapril

Lisinopril is not a pro drug and is excreted unchanged in the urine

In cases of overdosage, it can be removed from circulation by dialysis

CLINICAL USE

Its indications, contraindications and side effects are as those for all ACE inhibitors

Its long half-life allows for once a day dosing which aids patient compliance

Patients whose creatinine clearance ≥10 mL/min and ≤30 mL/min should be given the standard 5 mg/day dosage, at first

CONTINUED

For patients whose creatinine clearance is less than 10 mL/min, the dosage should start at 2.5 mg/day, adjusted over time according to the patient's blood pressure response

ADVERSE EFFECTS

Chills, infection

Dark urine, decreased urination

Difficulty swallowing or breathing

Hoarseness

Itching

CONTINUED

Rapid weight gain, stomach pain

Yellowing of skin or eyes (jaundice)

Abdominal pain, bloating, vomiting

Chest pain or tightness, dizziness, lightheadedness, fainting (syncope)

CONTINUED

Dry cough

Fever

Joint pain

Rash

Diarrhea, loss of taste, nausea

REVENUE OF LISINOPRIL

MARKET SHARE OF LISINOPRIL

THANK YOU

Presented By :- REEMA PUNIANI (M100700046)